Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Arthritis Research & Therapy

Figure 2

From: High mobility group box 1 contributes to anti-neutrophil cytoplasmic antibody-induced neutrophils activation through receptor for advanced glycation end products (RAGE) and Toll-like receptor 4

Figure 2

Cytotoxicity assay of neutrophils with different stimulations and dose–response curves for involved blocking antibodies and inhibitors. LDH release of neutrophils incubated with anti-TLR2 at 5 μg/ml, anti-TLR4 at 5 μg/ml, RAGE-Fc at 5 μM, MyD88 inhibitor at 20 μM or NF-κB inhibitor were measured. Involved blocking antibodies and inhibitors showed no significantly cytotoxicity (A) activating effect (B-F) to neutrophils. B-F also showed dose–response curves for involved blocking antibodies and inhibitors. Bars represent mean ± standard deviation (SD) of repeated measurements of three independent experiments. LDH, lactate dehydrogenase; MyD88, myeloid differentiation factor 88; NF-κB, nuclear factor kappa B; RAGE, receptor for advanced glycation end products; TLR, Toll-like receptor.

Back to article page